AbbVie Completes Acquisition of Aliada Therapeutics
AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie.
RA Capital Management Announces Close of $1.4 Billion Acquisition of Aliada Therapeutics by AbbVie
RA Capital Management, LP (RA Capital), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today ...
PharmTech11h
AbbVie Acquires Aliada Therapeutics, Gains Neuroscience Pipeline
AbbVie has completed its acquisition of Aliada Therapeutics which includes Aliada’s disease-modifying therapy for Alzheimer’s disease.
Le Lézard16h
Saskatchewan Blue Cross allows members to choose with the "Your Voice, Your Choice" program
Saskatchewan Blue Cross, a leading health and wellness solutions provider, is dedicated to making a meaningful difference in ...
Le Lézard16h
Tax tip - Extension of administrative policy for dental T4/T4A reporting
The T4 and T4A reporting requirements for employer- and payer-offered dental benefits, for issuers who would otherwise enter code 1, are waived again for 2024. This Canadian Dental Care Plan (CDCP) ...